Top 2020 US patentees reveal prosecution strategies Micron, Toyota and others reveal how they engage examiners, divide patent prosecution work and overcome Section 101 issues By Rani Mehta January 29 2021
How in-house fight infringers in ‘broken’ post-GDPR world Lawyers say while data correlation can help fight cybersquatters, domain enforcement is more time-consuming than ever before By Rani Mehta January 29 2021
Munich CJEU referral potential injunction ‘game changer’ Telecoms and pharma sources explain how altered validity standards would create new winners and losers in preliminary injunction proceedings By Charlotte Kilpatrick January 28 2021
The launch of Horizon Europe: The EU initiative for research and innovation Marco Stief of Maiwald takes a closer look at the key elements of the scientific research initiative that succeeded the Horizon 2020 framework programme By Maiwald & Marco Stief January 28 2021
Virtual trials creating hurdles for expert witness testimony IP litigators relay their recent experience of the logistical challenges of extracting witness testimony in an online courtroom By Charlotte Kilpatrick January 28 2021
Five NPEs reveal new IP monetisation plans Blackbird, Dominion Harbor, Acacia, Endpoint IP and Harfang IP share their goals for a pandemic-wrought 2021, including buying up cheap divested patents By Patrick Wingrove January 28 2021
3M trademark chief: COVID response was ‘strategy on steroids’ Colette Durst explains how she restructured the 3M team during COVID and why a pandemic is the perfect time to show IP worth By Incopro & Max Walters January 27 2021
Incoming health secretary unnerves pharma in-house counsel Senior in-house sources in innovator and generic drug companies reveal to Managing IP that they’re concerned about Xavier Becerra’s pharma antitrust record By Patrick Wingrove January 25 2021
ASCI moves in to clamp misleading COVID-19 claims in India Ranjan Narula and Daleep Kumar of RNA, Technology and IP Attorneys explain how the Advertising Standards Council of India is acting to prevent misleading claims about coronavirus cures and remedies By Daleep Kumar & Ranjan Narula & RNA Technology and IP Attorneys January 25 2021
Plaintiffs consider bench trials to combat litigation backlog Four in-house counsel, two private practice lawyers and one judge, Alan Albright, reveal how courts and lawyers are managing the COVID-induced trial holdup By Rani Mehta January 22 2021
CJEU cheese ruling boosts food makers’ GI enforcement A CJEU decision on Morbier cheese has clarified the depth of protection offered for distinctive food and drink products and created new options, counsel say By Max Walters January 22 2021
In-house: new university patent pool will ease licensing efforts Sources from Columbia University, Nantero and Viziv Technologies reflect on whether the University Technology Licensing Program will make licensing easier By Rani Mehta January 21 2021
Anti-anti-suit injunctions create ‘risky’ FRAND playing fields Industry sources say the friction in Ericsson v Samsung illustrates a rising trend of unhealthy FRAND negotiation tactics By Charlotte Kilpatrick January 21 2021
Monoclonal antibody biosimilars pose unique IP challenges In-house sources from the biosimilar industry explain why ‘low inventive step’ and process patents keep new monoclonal antibodies off the market By Charlotte Kilpatrick January 21 2021
District court 2020 rankings: top plaintiffs, defendants and firms WSOU Investments filed the most cases, Google was the most sued business, and Rabicoff Law and Fish & Richardson were the busiest firms, according to new data By Patrick Wingrove January 20 2021
USPTO should rework patent bar test rules, say in-house Counsel from IBM, Blaze Bioscience, and four other companies say the USPTO should expand the requirements for joining the patent bar to increase gender diversity By Rani Mehta January 14 2021
EU GMO Directive ‘stunts’ CRISPR patents Agricultural sources claim restrictive plant breeding regulations are holding back CRISPR patent filings in Europe By Charlotte Kilpatrick January 14 2021
Podcast: BMS and Bird & Bird on doing major deals in a pandemic Max Walters joins Sally Shorthose and James Baillieu of Bird & Bird and Henry Hadad of Bristol Myers Squibb to discuss how COVID-19 has shaped transactional work By Max Walters January 14 2021
Opinion: What open-source software can teach big pharma A new focus on early-stage collaborative medicine could revolutionise drug research By Charlotte Kilpatrick January 14 2021
The MIP Awards and IP STARS rankings 2021 Managing IP has released the timeline for publishing the results of the 2021 MIP Awards and IP STARS research By Kingsley Egbuonu January 14 2021
Counsel call for action over lingering bad-faith filers in China Despite legal reform, better training for examiners and stronger punishment of bad-faith filers is needed to tackle trademark squatting By Karry Lai January 13 2021
Landmark US trademark act ‘bolsters plaintiffs and fights fraud’ The Trademark Modernization Act, enacted two days after Christmas, helps plaintiffs obtain injunctive relief and ensures that Arthrex won’t affect the TTAB By Rani Mehta January 08 2021
German court rules against automated dispensing of medicinal products Christian Meyer of Maiwald explores a recent decision which prevents the distribution of medicinal products by means of an automatic dispenser from a foreign mail-order pharmacy By Christian Meyer & Maiwald January 07 2021
What counsel want from the new USPTO director Lawyers at Novartis, Siemens, Honeywell, Salesforce and elsewhere lay out the qualities and experience they think the new IP office head should have By Patrick Wingrove January 06 2021
